• Lantheus Holdings recently reported that its investigational PET imaging agent LNTH-2513 (18F-GP1) won SNMMI’s 2026 “Image of the Year” for clinical data showing high diagnostic accuracy in detecting acute deep vein thrombosis and associated pulmonary embolism.
• The recognition for LNTH-2513 highlights Lantheus’s efforts to expand platelet-targeted imaging, potentially broadening its future radiopharmaceutical footprint beyond oncology into thrombotic disease evaluation.
• We’ll now examine how this award-winning LNTH-2513 PET/CT data might shape Lantheus’s investment narrative around radiodiagnostic innovation and pipeline strength.

Find 46 companies with promising cash flow potential yet trading below their fair value.

Lantheus Holdings Investment Narrative Recap

To own Lantheus, you need to believe it can turn its radiopharmaceutical portfolio into a broader, durable business rather than a PYLARIFY story with pricing and share pressures. The LNTH-2513 SNMMI “Image of the Year” win showcases pipeline depth in thrombotic imaging but does not materially change the near term focus on PYLARIFY’s new formulation and reimbursement reset as the key catalyst, or the risk that pricing compression and concentration around one flagship product continue to weigh on sentiment.

Among recent announcements, the August 2025 FDA acceptance of the new high yield PYLARIFY formulation (with a March 2026 PDUFA date) remains most relevant to the LNTH-2513 news. Together, they frame how Lantheus is trying to balance near term prostate cancer imaging economics with longer term diversification into new indications, where agents like LNTH-2513 could eventually help reduce reliance on a single product if they progress successfully through development.

Yet against this encouraging innovation story, investors still need to be aware of how sustained PSMA pricing pressure and reimbursement shifts could...

Lantheus Holdings' narrative projects $1.9 billion revenue and $431.2 million earnings by 2029. This requires 7.4% yearly revenue growth and about a $152 million earnings increase from $279.0 million today.

Uncover how Lantheus Holdings' forecasts yield a $104.08 fair value, in line with its current price.

Exploring Other Perspectives

While consensus sees steady growth, the more optimistic analysts were already modeling revenue of about US$2.2 billion and earnings near US$741 million by 2029, suggesting LNTH-2513’s progress could further support their view that portfolio diversification can offset the risk of overreliance on PYLARIFY and intensifying pricing pressure.

Explore 6 other fair value estimates on Lantheus Holdings - why the stock might be worth as much as 88% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Lantheus Holdings research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Lantheus Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lantheus Holdings' overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.